ADC Therapeutics SA held its annual general meeting of shareholders on June 3, 2025. Shareholders approved the management report, annual financial statements, and consolidated financial statements for the year ended December 31, 2024. The members of the board of directors and the executive committee were discharged from liability for the year ended December 31, 2024. The net loss for the year ended December 31, 2024, will be carried forward. Several directors were elected or reelected, including Ron Squarer, Robert Azelby, Jean-Pierre Bizzari, Peter Hug, Ameet Mallik, Viviane Monges, Tyrell Rivers, Victor Sandor, and Timothy Coughlin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.